Canadian Red Cross announces financial assistance for people evacuated from Jasper due to wildfires in Alberta
$750 will be provided to households evacuated from their primary residence in JasperOTTAWA, July 30, 2024 (GLOBE NEWSWIRE) -- The...
Month: July 2024
Canadian Red Cross announces financial assistance for people evacuated from Jasper due to wildfires in Alberta
$750 will be provided to households evacuated from their primary residence in JasperOTTAWA, July 30, 2024 (GLOBE NEWSWIRE) -- The...
Zevra Therapeutics to Report Second Quarter 2024 Financial Results
Audio Webcast schedule to be held on August 13, 2024 at 4:30 p.m. ETCELEBRATION, Fla., July 30, 2024 (GLOBE NEWSWIRE)...
Evoke Pharma, Inc. Announces Reverse Stock Split
SOLANA BEACH, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily...
Milestone Scientific Secures Key Patent Approvals in the U.S. and Europe
ROSELAND, N.J., July 30, 2024 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE: MLSS), a leading developer of computerized drug delivery...
Neuronetics Announces the Closing of up to $90 Million Senior Secured Credit Facility with Perceptive Advisors
MALVERN, Pa., July 30, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing,...
ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference
Preclinical data showed strong antibody responses with no measurable pro-inflammatory T cell responses against AßO and support novel approach for...
Cassava Sciences Announces Expansion of Open-Label Extension Trials
Ongoing open-label extension trials of simufilam in Alzheimer’s disease to be extended by up to an additional 36 months. The...
Yamo Pharmaceuticals Announces Positive Topline Results from Phase 2 Study of L1-79 for the Treatment of the Core Symptoms of Autism
Data shows L1-79 offers a statistically significant improvement compared to placebo in socialization, as well as the investigator- and parent-rated...
NKGen Biotech Presents New Positive SNK01 Biomarker Data at the 2024 Alzheimer’s Association International Conference
SNK01, a cryopreserved autologous non-genetically modified NK cell product, is able to effectively reduce α-synuclein (α-syn) protein levels in the...
Better Health Outcomes for Seniors, Improved Access to Care and Reduced Environmental Footprint Are Top Achievements Noted in Alignment Healthcare’s 3rd Annual ESG Report
New data details Medicare Advantage company’s ongoing commitment to environmental, social and governance prioritiesORANGE, Calif., July 30, 2024 (GLOBE NEWSWIRE)...
Eyenovia & SGN Nanopharma Announce Collaboration Agreement to Develop Novel Treatment for Chronic Dry Eye Disease
The U.S. addressable market for Dry Eye Disease is valued at over $3 billion by independent sourcesNEW YORK, July 30,...
Nautilus Biotechnology Reports Second Quarter 2024 Financial Results
SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule proteome...
Silk Road Medical Celebrates Milestone of 100,000 Transcarotid Artery Revascularization (TCAR) Procedures
Studied across thousands of patients and supported by hundreds of clinical publications, the TCAR pioneer has continually delivered positive outcomes...
Scorpius Holdings Announces Removal of NYSE American Trading Suspension; Expected to Resume Normal Trading on August 2, 2024
DURHAM, N.C., July 30, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc. (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated...
CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference
BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for...
Ovid Therapeutics to Present at Upcoming August Investor Conferences
NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving...
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001
Phase 2 OVATION 2 Study of IMNN-001 administered with standard-of-care chemotherapy as first-line treatment demonstrates a hazard ratio of 0.74...
180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake
PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- PALO ALTO, Calif., July 30, 2024 (GLOBE NEWSWIRE) -- 180 Life...
Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Added to CVS Caremark Formularies for Commercially Insured Patients
CVS Caremark, the largest pharmacy benefit manager (PBM) in the United States, added VOQUEZNA® (vonoprazan) tablets to its national formularies...